id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-259668-nwezszhj	Ortiz, Alberto	Complement and protection from tissue injury in COVID-19	2020-10-04		.txt	text/plain	2618	129	37	Finally, preclinical studies in endotoxaemia, another hyperinflammation syndrome characterized by lung and kidney injury, suggest that cilastatin, an inexpensive drug already in clinical use, may provide tissue protection against hyperinflammation in COVID-19. In any case, this report suggests that assessing complement peptides may eventually contribute to define clusters of COVID-19 patients, as has been done for C3 glomerulopathies/immune complex-mediated membranoproliferative glomerulonephritis [11, 12] . In non-controlled case series and case reports, relatively positive results have been reported for the anti-C5 monoclonal antibody eculizumab, for C3 inhibitor AMY-101, for the mannan-binding lectin-associated serine protease 2 blocker narsoplimab (OMS721), for aliskiren and for nafamostat mesylate, a US Food and Drug Administration-approved anticoagulant agent that has broad-spectrum serine protease inhibitory activity, including for C1 esterase [2, [19] [20] [21] [22] [23] [24] [25] [26] . [3] emphasize, the fact that the SARS-CoV-2 cellular receptor ACE2 is expressed in lipid rafts may provide two mechanisms by which cilastatin may protect from severe COVID-19: (i) stabilizing ACE2 at the cell surface lipid rafts and preventing virus/ACE2 internalization and (ii) preventing hyperinflammation-induced tissue injury as observed in rat endotoxemia.	./cache/cord-259668-nwezszhj.txt	./txt/cord-259668-nwezszhj.txt